Navigation Links
Heptares to Moderate Panel on Global Business Development at Upcoming Boston Biotech East/West CEO Conference
Date:1/8/2014

WELWYN GARDEN CITY, England and BOSTON, January 8, 2014 /PRNewswire/ --

Heptares Therapeutics, the leading GPCR drug discovery and development company, notes that its President, Dan Grau, will moderate a panel discussion entitled "Global Entrepreneurs: Biotech Building Beyond Borders" (1:30-2:00pm Eastern time on 11 January) at the Boston Biotech East/West CEO Conference, which takes place at the Four Seasons Hotel, San Francisco, CA, USA on 11-12 January.

Mr Grau, Malcolm Weir (CEO), Fiona Marshall (CSO) and Barry Kenny (CBO) will attend the JPMorgan Healthcare conference, also in San Francisco, on 13-16 January.

For a full list of events at which Heptares will be present, please visit http://www.heptares.com

About Heptares Therapeutics

Heptares creates new medicines targeting clinically important, yet historically challenging, GPCRs (G protein-coupled receptors), a superfamily of drug receptors linked to a wide range of human diseases. Leveraging our proprietary structure-based drug design technology platform, we have built an exciting pipeline of novel drug candidates with the potential to transform the treatment of serious diseases, including Alzheimer's disease, ADHD, diabetes, schizophrenia, and migraine. Our pharmaceutical partners include Cubist, MorphoSys, Takeda, AstraZeneca and MedImmune, and we are backed by Clarus Ventures, MVM Life Science Partners, Novartis Venture Fund, the Stanley Family Foundation and Takeda Ventures. To learn more about Heptares, please visit http://www.heptares.com

HEPTARES is a registered trademark in the EU, Switzerland, US and Japan;

StaR is a registered trademark in the EU and Japan.


'/>"/>
SOURCE Heptares Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Heptares Initiates Clinical Study With First Selective Muscarinic M1 Receptor Agonist for Improving Cognition in Patients With Alzheimers Disease
2. Heptares Achieves First Research Milestone in Research Collaboration with Cubist
3. Heptares Augments Business Development Capabilities in Japan and Other Asian Territories
4. Heptares to Present at Boston Biotech BD and Future Leaders in the Biotech Industry Conferences
5. Heptares to Present at the 6th Annual European Life Sciences CEO Forum (5-6 March)
6. Heptares to Present at 5th CNS Partnering and Deal-Making Conference (13-14 SEPTEMBER)
7. Heptares and UK Medical Research Council Extend GPCR Collaboration
8. Turkish Diagnostic Imaging System Market Will Fluctuate, While Russian Market Will Grow Moderately Through 2022
9. Surveyed U.S. Rheumatologists are Moderately Satisfied with Biologic Agents and Xeljanz to Treat Rheumatoid Arthritis
10. Strong Efficacy Data Prompt Charleston Laboratories to Halt Phase 3 Study of CL-108 in Patients with Moderate to Severe Acute Pain
11. Greater Efficacy on Cognition and Function Over Current Treatments Remain Neurologists Top Unmet Need in Mild to Moderate Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... 2017   BioLife Solutions , Inc. (NASDAQ: ... clinical grade cell and tissue hypothermic storage and ... Rice , President and CEO, will be presenting at two ... & Renshaw 19 th Annual Global Investment Conference on ... Pacific time). The conference is being held at the New ...
(Date:9/6/2017)... , Sept. 6, 2017  Medical professionals ... and skills while treating their patients. Medical ... experience without involving patients. Simulation provides a ... can carry out procedures, refine techniques and ... Integration of new technology, such as augmented ...
(Date:9/6/2017)... NeuroRx, a clinical stage biopharma company developing the first oral ... granted Fast Track status by the US Food and Drug ... by NRX-101 (D-cycloserine + lurasidone). The company will shortly begin ... targeting patients who are admitted to Emergency Departments with ASIB ... ...
Breaking Medicine Technology:
(Date:9/21/2017)... ... September 21, 2017 , ... The American ... Health Services for professionals in the addiction treatment industry entitled: Special Investigations ... , Insurance companies and state and federal governments are increasingly scrutinizing the addiction ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... communities, nine governmental public health departments have been awarded five-year accreditation status through ... that the benefits of being served by a PHAB-accredited health department now ...
(Date:9/21/2017)... ... September 21, 2017 , ... Innovatum will demonstrate capabilities of ... Healthcare Conference 2017 in Chicago, IL on October 17-19, 2017. This unique development ... improving patient safety. , Microscan , a global technology leader in ...
(Date:9/21/2017)... ... September 21, 2017 , ... Japanese Zen artist couple, Fumie and Kentaro Mune, ... and 8th October at Miranda Kuo Gallery on Lower East Side, NYC. This exhibition ... Kodo mat. Wanderlust , one of the largest US yoga online media outlets ...
(Date:9/21/2017)... ... September 21, 2017 , ... Sagora Senior Living, ... Isle at Kingwood Assisted Living and Memory Care located at 24025 Kingwood Place ... 55 assisted living apartments, 43 memory care apartments and 23 extended care apartments. ...
Breaking Medicine News(10 mins):